Table 2.
Baseline and one-year follow-up laboratory and biomarker determinations in patients who completed treatment with diflunisal.
| VARIABLE | Visit 0 | Visit 1 | p |
|---|---|---|---|
| Laboratory and Biomarker Determinations | |||
| Hb (g/dL± SD) (n = 16) | 14.3 ± 1.7 | 14.0 ± 1.8 | 0.263 |
| eGFR (mL/min/1.73 m2, ± SD) (n = 16) | 60.6 ± 14.6 | 52.5 ± 14.7 | 0.036 |
| NT-proBNP (pg/mL, IQR) (n = 16) | 1815.0 (1132.5–3642.5) | 2020.0 (836.25–3997.5) | 0.272 |
| HsTnI (pg/mL, ± SD) (n = 9) | 154.6 ± 114.9 | 153.1 ± 137.8 | 0.971 |
| IL-6 (pg/mL, IQR) (n = 9) | 2.7 (2.4–36.2) | 3.0 (1.3–6.3) | 0.08 |
| TIM-1 (pg/mL, ± SD) (n = 9) | 199.6 ± 104.2 | 232.8 ± 131.6 | 0.359 |
| Gal3 (pg/mL, ± SD) (n = 9) | 7544.7 ± 2307.5 | 8945.4 ± 3926.3 | 0.303 |
| hsCPR (mg/L, ± SD) (n = 9) | 2.4 ± 2.8 | 2.3 ± 1.7 | 0.952 |
| CK-MB (ng/mL, ± SD) (n = 9) | 1.7 ± 0.7 | 2.6 ± 1.3 | 0.165 |
| NT-ProANP (ng/mL, ± SD) (n = 9) | 65.2 ± 12.6 | 64.5 ± 12.2 | 0.790 |
| PTH (pg/mL, ± SD) (n = 9) | 78.9 ± 32.0 | 90.0 ± 43.0 | 0.418 |
| Klotho (pg/mL, ± SD) (n = 9) | 535.4 ± 124.6 | 564.5 ± 169.4 | 0.669 |
| FGF-23 (RU/mL, IQR) (n = 9) | 257 (126.5–328.5) | 149 (131–207) | 0.499 |
| VitD (ng/mL, ± SD) (n = 9) | 33.1 ± 13.2 | 34.7 ± 9.6 | 0.776 |
| RBP4 (µg/mL, ± SD) (n = 9) | 28.0 ± 10.5 | 33.6 ± 13.0 | 0.020 |
| TIMP-1 (ng/mL, ± SD) (n = 9) | 183.5 ± 31.3 | 201.8 ± 33.1 | 0.069 |
| TIMP-2 (ng/mL, ± SD) (n = 9) | 116.9 ± 12.6 | 124.0 ± 22.9 | 0.371 |
| MMP-2 (ng/mL, ± SD) (n = 9) | 330.2 ± 47.0 | 339.1 ± 54.9 | 0.619 |
| MMP-9 (ng/mL, IQR) (n = 9) | 365 (228–571) | 497.5 (227.8–966.0) | 0.515 |
| Prealbumin (mg/dL, IQR) (n = 9) | 26.5 (19.6–28.7) | 32.3 (27.3–33.6) | 0.008 |
Quantitative data following a normal distribution are presented as mean ± standard deviation (SD), those not normally distributed are displayed as median (IQR = interquartile range), and qualitative variables are presented as percentages. CK-MB = creatine kinase-myocardial band; eGFR = estimated glomerular filtration rate; FGF-23 = fibroblast growth factor 23; GAL-3 = galectin 3; Hb = hemoglobin; hsCRP = high sensitivity C-reactive protein; hsTnI = high-sensitivity troponin I; IL-6 = interleukin 6; MMP-2 = matrix metallopeptidase-2; MMP-9 = matrix metallopeptidase-9; NT-proANP = N-terminal pro–atrial natriuretic peptide; NT-proBNP = N-terminal pro-brain natriuretic peptide; PTH = parathyroid hormone; RBP4 = retinol binding protein 4; TIM-1 = T cell immunoglobulin and mucin domain 1; TIMP-1 = tissue inhibitors of metalloproteinases-1; TIMP-2 tissue inhibitors of metalloproteinases-2.